鼠白细胞介素15真核表达质粒的构建及活性鉴定

从经PMA刺激的小鼠脾细胞中提取总RNA, 采用RT-PCR技术获得鼠白细胞介素15(mIL-15)基因, 将其克隆至真核表达质粒VR1012中, 转染COS-7细胞, 将转染细胞裂解, Western blot检测. 表明获得了mIL-15真核表达载体, 其具有完整的带有信号肽的mIL-15序列, 重组结果正确, Western blot检测阳性. 并获得有生物活性的mIL-15蛋白.     

小鼠CD47-Fc融合蛋白表达载体构建、表达纯化及其生物学活性研究

构建CD47重组蛋白真核表达载体pcDNA3.1(-)-CD47-Fc.在真核细胞293T中成功表达重组蛋白,经亲和层析获得较高纯度重组蛋白CD47-Fc.通过免疫荧光染色、流式细胞技术和细胞黏附实验测定重组蛋白CD47-Fc的生物学活性,结果显示制备的CD47-Fc蛋白可与腹腔巨噬细胞表面的SIRPα很好地相互作用,制备的CD47-Fc具有较高的生物学活性.     

巴尔通体HBPC蛋白原核重组表达及抗原性研究

为了寻找可用于巴尔通体(Bartonella)检测的特异性抗原,利用PCR方法从巴尔通体厦门分离株(B.tribocorum_XM)的基因组DNA中扩增出血红素结合蛋白C(HBPC)蛋白基因,并将该基因的编码区克隆到pGEX-4T-1原核表达载体中,构建带GST标签的融合蛋白重组表达载体,并转化大肠杆菌(Escherichia coli DH5α),诱导表达GST-HBPC,通过亲和层析技术纯化GST-HBPC.最后运用蛋白质斑点印迹试验(Western blot)和间接ELISA法检验GST-HBPC是否具有抗原性.结果表明,所构建的表达载体可在大肠杆菌中大量表达GST-HBPC,Western blot和间接ELISA显示GST-HBPC能够特异性地与感染动物血液样本发生免疫反应.因此,体外重组的巴尔通体抗原蛋白HBPC可作为潜在的抗原用于巴尔通体血清学免疫检测.     

人凝血因子Ⅶ在CHO/DG44细胞中的表达

PCR法扩增FⅦ基因,构建重组表达质粒FⅦ-pOptiVEC,酶切、测序鉴定.脂质体法将FⅦ-pOptiVEC质粒转入CHO/DG44细胞,并用氨甲喋呤(MTX)进行分级加压筛选,获得高表达重组FⅦ蛋白的阳性细胞克隆.亲和层析法纯化FⅦ,并通过Western-blot检测蛋白表达情况.采用FⅦ促凝活性检测试剂盒(凝固法)检测FⅦ的凝血活性.结果表明筛选出的细胞克隆能稳定表达目的蛋白,MTX加压使其表达量明显升高.促凝活性检测结果证明获得的FⅦ蛋白具有凝血活性.     

表达EGFR与HER2双抗体融合蛋白腺病毒载体研究

构建携带Cetuximab全长抗体与Herstatin C末端79个氨基酸(Herin)融合蛋白的腺病毒,探讨其在体外表达情况,及其与EGFR和HER2的结合能力.通过PCR,将抗体cetuximab基因与编码Herstatin C末端79个氨基酸(Herin)的序列融合,构建携带西妥昔单抗全长基因与Herin融合基因的腺病毒穿梭载体pDC339-AT2一Herin,并在293细胞内包装成重组病毒Ad5-AT2-Herin.通过酶联免疫吸附试验(ELISA)检测Ad5-AT2-Herin表达全长抗体融合蛋白的体外表达量;应用Western印迹法检测所表达全长抗体轻重链的完整性及均衡性;应用间接免疫荧光法(IFA)检测所表达的融合蛋白与EGFR(+)Her2(-)的A431细胞,以及EGFR(-)Her2(+)的SK-OV-3细胞膜结合的特异性.ELISA检测分析表明,AdS-AT2-Herin在293细胞中的表达量为209.3 ng/mL-317.3 ng/mL;Western blot显示轻重链表达平衡,大小符合预期;间接免疫荧光(IFA)显示腺病毒表达的融合蛋白与A431细胞表面受体EGFR及SK-OV-3细胞表面受体Her2均能特异性结合.成功构建携带EGFR和HER2双特异性抗体基因的腺病毒载体Ad5-AT2-Herin,该载体在体外能高效表达双特异性抗体蛋白AT2-Herin,而且AT2-Herin蛋白能在体外与EGFR和HER2特异结合.     

柔嫩艾美耳球虫Serpin基因在293T细胞中的表达

为了检测柔嫩艾美耳球虫(Eimeria tenella,Et)丝氨酸蛋白酶抑制剂(Serine protease inhibitor,Serpin)基因(EtSerpin)在真核细胞293T中的表达情况,以Et孢子化卵囊cDNA为模板,经PCR扩增含完整Serpin开放阅读框的序列,将其克隆至pGEM-Teasy载体,构建pGEM-Teasy-EtSerpin质粒,双酶切回收目的片段后与相应酶切的真核表达载体pCAGGS连接,构建真核重组表达质粒pCAGGS-EtSerpin.该重组质粒经酶切和测序鉴定正确后转染293T细胞,用间接免疫荧光法和Western blot鉴定EtSerpin基因的表达情况,间接免疫荧光实验可以检测到红色荧光,Western blot结果显示出大小约45.5kDa的目的蛋白条带,结果表明构建的EtSerpin可以在293T细胞中获得表达.     

原核系统表达的鸡白细胞介素-10的鼠抗血清体内研究的初步分析

目的获得鸡白介素-10(chIL-10)的原核表达产物,制备鼠抗血清,分析与真核系统表达的chIL-10的反应原性。方法采用RT-PCR从经脂多糖(LPS)体外刺激的鸡外周血淋巴细胞中扩增编码成熟IL-10的基因,克隆至原核表达载体pET-30a(+),成功构建原核重组质粒pET-chIL-10;转化至大肠杆菌DH5α中IPTG诱导表达,切下含有重组蛋白的SDS-PAGE胶条,免疫制备鼠抗血清;分别与包含信号肽和去除信号肽的chIL-10真核表达细胞系CHO-euchIL-10F和CHO-euchIL-10M进行间接免疫荧光抗体试验(IFA)和蛋白免疫印迹试验(Western blot),验证有无反应性。结果成功构建chIL-10的原核表达载体pET-chIL-10,获得了高效价的鼠抗血清,能与表达chIL-10的真核细胞系反应。结论原核表达的chIL-10特异性鼠抗血清将能用于体内研究的检测。     

人血管紧张素Ⅱ2型受体AT2R重组细胞系的构建与鉴定

目的:构建人血管紧张素Ⅱ2型受体(hAT2R)过表达稳定细胞系,探讨AT2R激动剂Compound 21等对前列腺癌细胞的作用及机制.方法:构建含hAT2R基因的慢病毒表达载体pLV-CMV-hAT2R-IRES-eGFP并包装成慢病毒.将重组慢病毒载体pLV-CMV-IRES-eGFP-hAT2R感染前列腺癌细胞,并利用流式细胞术筛选出单克隆细胞株,RT-PCR及Western blot方法检测重组细胞系中hAT2R表达水平,使用AT2R激动剂CGP42112检测受体功能.结果:重组慢病毒载体感染PC-3、DU145前列腺癌细胞24 h后均能观察到eGFP表达,用流式细胞术分别筛选出单克隆细胞株,RT-PCR及Western blot检测结果显示目的基因hAT2R在两株重组细胞系中表达显著升高,CGP42112处理24 h后,重组细胞系细胞活力较正常PC-3、DU145细胞显著降低.结论:成功构建hAT2R过表达稳定细胞系.     

狂犬病毒核蛋白在昆虫细胞中的表达及免疫原性的研究

目的在昆虫细胞中表达出狂犬病毒核蛋白(NP),并探讨重组NP的免疫原性.方法采用杆状病毒表达系统在Sf9昆虫细胞中表达狂犬病毒核蛋白,用直接免疫荧光(DFA)、SDS-PAGE和Western blot对表达产物进行检测和分析,以感染重组杆状病毒的昆虫细胞裂解液免疫小鼠,检测表达产物的免疫原性.结果重组杆状病毒在昆虫细胞中获得表达,免疫小鼠可产生抗核蛋白抗体.结论在Sf9昆虫细胞中表达出狂犬病毒核蛋白,重组产物具有生物活性.     

构建重组人CatSperl特异抗原原核表达载体

目的:构建重组人Catsper1特异抗原(含胞外区、钙选择孔区和破伤风类毒素通用T细胞表位TT580-590)原核表达载体并表达重组抗原.方法:设计引物,以RT-PCR法扩增人CatSper1的整个跨膜区DNA片段,利用重叠PCR方法合成重组人CatSper1特异抗原DNA片段,并插入到pET-21b和pET-21b-Trx(硫氧还蛋白)的原核表达载体.测序鉴定后转化工程菌株E. coli BL21(DE3)进行诱导表达,并纯化表达的重组蛋白.用TricineSDS-PAGE和Western blotting分析重组蛋白的表达情况.结果:成功构建pET-21b-Catsper1特异抗原和pET-21b-Trx-Catsper1特异抗原原核表达载体,并在BL21(DE3)中诱导表达重组蛋白.Tricine-SDS-PAGE和Western blotting鉴定表明,已获得重组人CatSper1特异抗原包涵体和纯化的可溶重组Trx-Catsper1特异抗原.结论:成功在原核表达系统表达重组人Catsperl特异抗原.     

导向溶栓分子scFv-UK32中连接肽的引入和在昆虫细胞中的表达

为了提高重组导向溶栓分子scFv-UK32的溶纤活性,通过重组PCR方法在编码scFv与UK32的碱基之间引入编码KLGGGG连接肽的碱基序列,并克隆到转移载体pBacPAK9上,通过与线性病毒DNA BacPAK6/Bsu36I digest共转染到昆虫细胞Sf 9内,进行表达。表达产物分泌到上清中,共转染后第5d(天)用纤维平板法测得Sf 9细胞上清溶纤活性达到107 IU/mL,比未引入连接肽的scFv-UK32的表达活性(25 IU/mL)高。ELISA实验表明共转染上清具有明显对活化血小板特异结合能力。Western Blotting实验表明共转染上清可与Pro-UK的单抗特异结合。     

A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin

Antibodies and growth factors have been chemically coupled to different toxins to produce cytotoxic molecules that selectively kill cells bearing appropriate antigens or receptors. Antibody-toxin conjugates (immunotoxins) produced using conventional chemical coupling techniques have several undesirable characteristics. The smallest binding unit of an antibody is an Fv fragment which consists of a light and heavy chain variable domain. Recently, active single chain Fv fragments of antibodies have been produced in Escherichia coli by attaching the light and heavy chain variable domains together with a peptide linker. Here we describe the construction and expression in E. coli of a single chain antibody toxin fusion protein, anti-Tac(Fv)-PE40, in which the variable regions of anti-Tac, a monoclonal antibody to the p55 subunit of the human interleukin-2 receptor, are joined in peptide linkage to PE40, a modified form of Pseudomonas exotoxin lacking its binding domain. Anti-Tac(Fv)-PE40 was very cytotoxic to two interleukin-2 receptor-bearing human cell lines but was not cytotoxic to receptor-negative cells.     

Localization of the binding site for the human high-affinity Fc receptor on IgG

A major pathway in the clearance of pathogens involves the coating of the pathogen with specific antibodies, and the binding of the antibody Fc region to cell receptors. This can trigger engulfment of the pathogen by phagocytes or lysis by killer cells. By oligonucleotide site-directed mutagenesis we have engineered a single amino acid change in a mouse IgG2b antibody (Glu 235----Leu) which now enables the antibody to bind to the FcRI (high affinity) receptor on human monocytes with a 100-fold improvement in affinity. This indicates that Leu 235 is a major determinant in the binding of antibody to FcRI and that the receptor may interact directly with the region linking the CH2 domain to the hinge. Tailoring the affinity of antibodies for cell receptors could help dissect their role in clearing pathogen.     

PI3K/Akt signaling pathway involved in regulation of T lymphocyte activation and apoptosis mediated by CD3ε

To study the expression and kinase activity of phosphatidylinositol 3′ -kinase (PI3K) and protein kinase B (PKB or Akt) during activation and apoptosis of human Jurkat T lymphocytes (TJK) with stable expression of CD8ε chimera fused human CD8α extracellular and transmembrane domains to intracellular domain of mouse CD3ε, Western blot, kinase activities detection and immunoprecipitation were carried out. It was shown that Jurkat cells with expression of wild type chimera CD8ε died by apoptosis after continuous stimulation of anti-CD8 monoclonal antibody. The expressions of PI3K and Akt, and the kinase activity of Akt remarkably increased during the process. However, this phenomenon did not occur in the Jurkat cells (T1JK) with expression of the mutant of CD8ε chimera (Y170F), suggesting that PI3K/Akt signaling pathway is involved in activation and apoptosis of T lymphocyte mediated by CD3ε.     

抗人骨桥蛋白单克隆抗体制备及其特异性研究

利用RT-PCR技术克隆人骨桥蛋白(hOPN)基因,构建OPN原核表达质粒pET-32a(+)-hOPN,转化BL21菌株,经IPTG诱导表达重组人骨桥蛋白(rhOPN).以纯化的rhOPN为免疫原,免疫BABL/c小鼠,取其脾细胞与小鼠骨髓瘤细胞NS1融合.通过有限稀释法进行克隆和间接ELISA筛选,获得抗人OPN蛋白单克隆抗体杂交瘤细胞株,以ELISA、Western blot对抗体特异性进行鉴定.通过竞争抑制试验对单克隆抗体识别抗原位点进行分析.结果共获得2株抗人OPN单克隆抗体,分别命名为8F1和2B5,亚型测定皆为IgG1.通过细胞侵袭抑制试验检测,2株抗人OPN mAb皆能很好地抑制细胞迁移.本研究成功获得了抗人骨桥蛋白的特异性单克隆抗体,为进一步研究OPN蛋白在自身免疫病和肿瘤中的功能提供了重要的工具.     

Antibodies inhibit prion propagation and clear cell cultures of prion infectivity

Prions are the transmissible pathogenic agents responsible for diseases such as scrapie and bovine spongiform encephalopathy. In the favoured model of prion replication, direct interaction between the pathogenic prion protein (PrPSc) template and endogenous cellular prion protein (PrPC) is proposed to drive the formation of nascent infectious prions. Reagents specifically binding either prion-protein conformer may interrupt prion production by inhibiting this interaction. We examined the ability of several recombinant antibody antigen-binding fragments (Fabs) to inhibit prion propagation in cultured mouse neuroblastoma cells (ScN2a) infected with PrPSc. Here we show that antibodies binding cell-surface PrPC inhibit PrPSc formation in a dose-dependent manner. In cells treated with the most potent antibody, Fab D18, prion replication is abolished and pre-existing PrPSc is rapidly cleared, suggesting that this antibody may cure established infection. The potent activity of Fab D18 is associated with its ability to better recognize the total population of PrPC molecules on the cell surface, and with the location of its epitope on PrPC. Our observations support the use of antibodies in the prevention and treatment of prion diseases and identify a region of PrPC for drug targeting.     

A chimaeric receptor allows insulin to stimulate tyrosine kinase activity of epidermal growth factor receptor

The cell surface receptors for insulin and epidermal growth factor (EGF) appear to share a common evolutionary origin, as suggested by structural similarity of cysteine-rich regions in their extracellular domains and a highly conserved tyrosine-specific protein kinase domain. Only minor similarity is found outside this catalytic domain, as expected for receptors that have different ligand specificities and generate different biological signals. The EGF receptor is a single polypeptide chain but the insulin receptor consists of distinct alpha and beta subunits that function as an alpha 2 beta 2 heterotetrameric receptor complex. Provoked by this major structural difference in two receptors that carry out parallel functions, we have designed a chimaeric receptor molecule comprising the extracellular portion of the insulin receptor joined to the transmembrane and intracellular domains of the EGF receptor to investigate whether one ligand will activate the tyrosine kinase domain of the receptor for the other ligand. We show here that the EGF receptor kinase domain of the chimaeric protein, expressed transiently in simian cells, is activated by insulin binding. This strongly suggests that insulin and EGF receptors employ closely related or identical mechanisms for signal transduction across the plasma membrane.     

T-cell recognition of a chimaeric class II/class I MHC molecule and the role of L3T4

In addition to expressing clonally distributed antigen-specific and major histocompatibility complex (MHC)-restricted receptors, T cells also express non-clonally distributed surface molecules that are involved in T-cell function. Among the most intriguing of the latter are L3T4 and Lyt 2, which are expressed on individual T lymphocytes in striking, though not absolute, concordance with their restriction by either class II or class I MHC determinants, and which are thought to contribute to the overall avidity of T-cell interactions by binding to monomorphic determinants on class II and class I MHC molecules, respectively. To examine the ability of T cells to recognize a single class II domain in the absence of the remainder of the Ia molecule, as well as to evaluate the structural basis for the putative interaction of L3T4 with Ia, a recombinant class II/class I murine MHC gene was constructed and introduced into mouse L cells. Here we demonstrate that a subset of class II allospecific cytotoxic T lymphocytes (CTL) can specifically recognize and lyse L-cell transfectants expressing an isolated polymorphic A beta 1 domain, and that anti-L3T4 antibody can block such killing, a result inconsistent with the highly conserved membrane-proximal domains of Ia acting as unique target sites for L3T4 binding.     

绿色荧光蛋白标记的NTE活性域表达载体的构建及表达 

利用含有特定限制性内切酶识别位点的引物，通过聚合酶链式反应扩增出人神经病靶标酯酶活性域的编码序列，经T载体克隆测序正确后，双酶切回收特异片段定向插入到增强型绿色荧光表达载体pEGFPN3中，通过酶切反应鉴定，构建了绿色荧光蛋白标记的神经病靶标酯酶活性域的融合表达载体pNESTEGFP。采用脂质体转染的方法将其转染到人神经瘤母瘤细胞SHSY5Y中，用荧光显微镜观察发现神经病靶标酯酶活性域分布于细胞质中，而且没有导致内质网膜的聚集，表明表达载体成功构建和表达。     

Progress in crystallization of major histocompatibility complex class I in vertebrates

The major histocompatibility complex(MHC)of proteins that exists in all vertebrates is encoded by a cluster of genes associated with the immune response and related functions.MHC is divided into MHC I,II,and III;MHC I is involved in antigenic presentation,binding T cell receptors,and leading ultimately to specific cellular immune responses.The complicated functions of MHC I are determined by the nature of the complex.The crystal structure of MHC I has been solved for many animals,revealing the relationship between spatial structure and function.MHC I consists of an a heavy chain and a b2m light chain,both ligated non-covalently to a complex when a peptide is bound to the antigenic-binding groove.The a heavy chain is divided into an extracellular domain,a transmembrane domain,and an intracellular domain.The extracellular domain consists of sub-regions a1,a2,and a3.The a1 and a2 together form the antigenic-binding groove and bind antigenic peptides with 8–10 amino acid residues.MHC I can form a stable spatial structure;however,it should be noted that there are differences in the structure of MHC I among animal species,including anchored amino acids in binding peptides,binding sites,molecular distance,crystallization conditions,etc.Here,progress in determination of the crystal structure of human,mouse,chicken,non-human primate,and swine MHC I is described in detail.